mgcd 265 analog (TargetMol)
TargetMol is a verified supplier 
TargetMol manufactures this product 
93
Structured Review
TargetMol
mgcd 265 analog
Mgcd 265 Analog, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgcd/MGCD-265+analog/pmc12718461-55-0-3
Average 93 stars, based on 1 article reviews
Mgcd 265 Analog, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgcd/MGCD-265+analog/pmc12718461-55-0-3
Average 93 stars, based on 1 article reviews
mgcd 265 analog - by Bioz Stars,
2026-10
93/100 stars
Images
1) Product Images from "Protocol for high-content drug screening using tumor organoids on a 384-pillar plate platform"
Article Title: Protocol for high-content drug screening using tumor organoids on a 384-pillar plate platform
Journal: STAR Protocols
doi: 10.1016/j.xpro.2025.104250
Figure Legend Snippet:
Techniques Used: Recombinant, Membrane, Software, Imaging
Related Articles
Recombinant:Article Title: ALKBH5 reverses romidepsin-mediated anti-multiple myeloma activity via regulation of m6A modification of FOXM1. Article Snippet: Multiple myeloma (MM), a prevalent hematological malignancy, is characterized by the abnormal proliferation and accumulation of plasma cells within the bone marrow.. ALKBH5, an RNA demethylase, is implicated in various tumor-related processes, yet its role in myeloma remains insufficiently understood.. In this study, we revealed that elevated ALKBH5 expression correlates with poor MM prognosis. Article Title: Protocol for high-content drug screening using tumor organoids on a 384-pillar plate platform Article Snippet: Membrane:Article Title: ALKBH5 reverses romidepsin-mediated anti-multiple myeloma activity via regulation of m6A modification of FOXM1. Article Snippet: Multiple myeloma (MM), a prevalent hematological malignancy, is characterized by the abnormal proliferation and accumulation of plasma cells within the bone marrow.. ALKBH5, an RNA demethylase, is implicated in various tumor-related processes, yet its role in myeloma remains insufficiently understood.. In this study, we revealed that elevated ALKBH5 expression correlates with poor MM prognosis. Article Title: Protocol for high-content drug screening using tumor organoids on a 384-pillar plate platform Article Snippet: Software:Article Title: ALKBH5 reverses romidepsin-mediated anti-multiple myeloma activity via regulation of m6A modification of FOXM1. Article Snippet: Multiple myeloma (MM), a prevalent hematological malignancy, is characterized by the abnormal proliferation and accumulation of plasma cells within the bone marrow.. ALKBH5, an RNA demethylase, is implicated in various tumor-related processes, yet its role in myeloma remains insufficiently understood.. In this study, we revealed that elevated ALKBH5 expression correlates with poor MM prognosis. Article Title: Protocol for high-content drug screening using tumor organoids on a 384-pillar plate platform Article Snippet: Imaging:Article Title: ALKBH5 reverses romidepsin-mediated anti-multiple myeloma activity via regulation of m6A modification of FOXM1. Article Snippet: Multiple myeloma (MM), a prevalent hematological malignancy, is characterized by the abnormal proliferation and accumulation of plasma cells within the bone marrow.. ALKBH5, an RNA demethylase, is implicated in various tumor-related processes, yet its role in myeloma remains insufficiently understood.. In this study, we revealed that elevated ALKBH5 expression correlates with poor MM prognosis. Article Title: Protocol for high-content drug screening using tumor organoids on a 384-pillar plate platform Article Snippet: |